Expert Interview
Reviewing the recent Duchenne Muscular Dystrophy Data from Wave Life Sciences on their exon 53 skipper, WVE-N531
Ticker(s): WVE, SRPT, RNA, NS PharmaInstitution: Duke University
- Former Co-Director of Duke Children's Neuromuscular Program & Professor of Neurology and Pediatrics at Duke, recently made a career change and is now exclusively focused on clinical trials.
- Treated hundreds of neuromuscular patients, including 150 DMD patients of all ages in 2023
- Actively involved in clinical research and many trials with a focus on pedicatric neuromuscular diseases; PI on multiple DMD studies including an Exon 53 skipping specific study.
How many DMD patients do you treat?
Added By: ben_adminWhat are your opinions of the data reported on WVE-N531?
Added By: ben_adminHow does the dystrophin level increases seen compare to other Exon skippers?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
